• Arcturus Therapeutics Announces Positive Interim ARCT-021 Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

    22 days ago - By San Diego Biotechnology

    SAN DIEGO--- $ARCT Clinicaltrial-Arcturus Therapeutics Announces Interim ARCT-021 Phase 1/2 Study Results, and Up to $220 Million in Additional Financial Commitments from Singapore...
    Read more ...